A
Acurx Pharmaceuticals, Inc. (ACXP)
NCM – Real Time Price. Currency in USD
1.52
+0.10 (7.04%)
At close: Jun 26, 2026, 4:00 PM EDT
1.48
-0.04 (-2.63%)
After-hours: Jun 26, 2026, 7:55 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.52
+0.10 (7.04%)
At close: Jun 26, 2026, 4:00 PM EDT
1.48
-0.04 (-2.63%)
After-hours: Jun 26, 2026, 7:55 PM EDT
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
| Name | Position |
|---|---|
| Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D. | Medical Director |
| Mr. David P. Luci CPA, Esq., J.D. | Co-Founder, President, CEO, Corporate Secretary & Director |
| Mr. Robert G. Shawah CPA | Co-Founder & CFO |
| Mr. Robert J. DeLuccia | Co-Founder & Executive Chairman |
| Date | Type | Document |
|---|---|---|
| 2026-05-11 | 10-Q | acxp-20260331x10q.htm |
| 2026-05-07 | CORRESP | filename1.htm |
| 2026-05-04 | S-1 | tm2611792d1_s1.htm |
| 2026-04-29 | D | |
| 2026-04-16 | 8-K | tm2611957d1_8k.htm |
| 2026-03-12 | S-8 | tm267891d1_s8.htm |
| 2026-03-12 | 10-K | acxp-20251231x10k.htm |
| 2026-03-09 | 8-K | tm268319d1_8k.htm |
| 2026-02-09 | CORRESP | filename1.htm |
| 2026-02-02 | S-1 | tm264593-1_s1.htm |